AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...